Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02955329 · ClinicalTrials.gov registry record · Phase 3
Vaping THC From Electronic Cigarettes
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT02955329 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 8 participants.
The verdict
NCT02955329, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study aims to understand THC pharmacology and the safety of cannabis vaping, including the pharmacology and safety of co-administration of nicotine and THC. The study is designed as a within-subjects single-blinded crossover study. Fourteen smokers of tobacco cigarettes and cannabis will switch between three conditions, namely: (a) vaping cannabis leaf, (b) vaping tobacco containing nicotine and (c) vaping a combination of cannabis leaf and tobacco containing nicotine. All participants will vape each product with the PAX loose-leaf vaporizer. The study will be conducted during three outpatient visits separated by at least 48 hours. The order of treatment (cannabis leaf, tobacco with nicotine, cannabis leaf \& tobacco with nicotine) will be counterbalanced between subjects. Subjects will be blinded to the content of the vaporizer on the study day but will be told during screening that they will vape cannabis alone, tobacco alone, and cannabis plus tobacco with nicotine.
Interventions
- DRUG Nicotine
- DRUG Cannabis
- DEVICE PAX Loose Leaf Vaporizer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2019-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02955329
The ClinicalTrials.gov registry entry for NCT02955329 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nicotine is the first listed.
NCT02955329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02955329 about?
NCT02955329 is a clinical study titled "Vaping THC From Electronic Cigarettes". This study aims to understand THC pharmacology and the safety of cannabis vaping, including the pharmacology and safety of co-administration of nicotine and THC. The study is designed as a within-subjects single-blinded crossover study. Fourteen smokers of tobacco cigarettes and cannabis will switch...
What is the current status of trial NCT02955329?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2019-03-20. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT02955329?
The interventions under investigation include: Nicotine (DRUG), Cannabis (DRUG), PAX Loose Leaf Vaporizer (DEVICE).
Who is sponsoring clinical trial NCT02955329?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.